MYGN — Myriad Genetics, Inc.

Summary of Myriad Genetics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $210 million, exceeding the high end of the preannounced range; a 4% growth when excluding the impact of UnitedHealthcare's GeneSight decision.
• Testing Volume: 382,000 test results delivered in Q4.
• Adjusted Gross Margin: 70%, down 190 basis points year-over-year due to revenue headwinds from GeneSight.
• Adjusted EBITDA: $14.3 million; adjusted EPS of $0.04, up from the previous year.
• Full Year Revenue: $824.5 million, with over 1.5 million test reports generated.

2. Strategic Updates and Business Highlights

• Oncology Testing: MyRisk volume grew 14% year-over-year; Prolaris test volume grew 12% due to targeted investments in the urology market.
• Mental Health: GeneSight volume increased by 9% year-over-year, with a record number of ordering clinicians.
• New Product Launches: The expanded MyRisk panel launched in Q4, with plans for disease-specific panels in Q2 2026. The Alpha launch of the Precise MRD test for breast cancer is set for next week.
• Sales and Marketing Investments: Over $35 million planned for enhancing commercial capabilities and expanding the sales team, particularly in oncology.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $860 million to $880 million, with adjusted gross margins between 68% and 69%.
• Q1 Revenue Expectation: $200 million to $203 million, reflecting a 2% to 4% growth year-over-year.
• Long-term Growth: Management expressed confidence in returning to high single-digit growth rates by 2027, driven by new product launches and improved execution.

4. Bad News, Challenges, or Points of Concern

• GeneSight Revenue Impact: The average revenue per test declined by 2% year-over-year, primarily due to UnitedHealthcare's policy change, which negatively affected revenue by $8.1 million.
• Prenatal Testing Decline: Volume in prenatal testing decreased due to prior order management disruptions, with expectations for continued challenges in Q1 2026.
• ASP Pressure: Anticipated modest headwinds in average selling prices across the portfolio, attributed to payer mix changes and competitive dynamics.

5. Notable Q&A Insights

• MRD Launch Strategy: Management plans to carefully manage the rollout of the Precise MRD test, focusing on user experience and operational efficiency before scaling up.
• Commercial Strategy Changes: A shift in sales strategy to focus on specialized teams for different product lines, aiming for improved execution and market penetration.
• Customer Engagement: There is optimism about winning back customers affected by previous operational issues, with a focus on expanding the customer base and cross-selling multiple assays.
• Payer Dynamics: The company is seeing a more balanced payer portfolio, which should stabilize revenue despite previous headwinds.

Overall, Myriad Genetics is positioned for growth with a strong pipeline of products and strategic investments, despite facing challenges in certain areas, particularly related to pricing and prenatal testing.